FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2252279491> ?p ?o ?g. }

• W2252279491 endingPage "e0143433" @default.
• W2252279491 startingPage "e0143433" @default.
• W2252279491 abstract "Background Evidence favoring earlier HIV ART initiation at high CD4+ T-cell counts (CD4>350/uL) has grown, and guidelines now recommend earlier HIV treatment. However, the cost of providing ART to individuals with CD4>350 in Sub-Saharan Africa has not been well estimated. This remains a major barrier to optimal global cost projections for accelerating the scale-up of ART. Our objective was to compute costs of ART delivery to high CD4+count individuals in a typical rural Ugandan health center-based HIV clinic, and use these data to construct scenarios of efficient ART scale-up. Methods Within a clinical study evaluating streamlined ART delivery to 197 individuals with CD4+ cell counts >350 cells/uL (EARLI Study: NCT01479634) in Mbarara, Uganda, we performed a micro-costing analysis of administrative records, ART prices, and time-and-motion analysis of staff work patterns. We computed observed per-person-per-year (ppy) costs, and constructed models estimating costs under several increasingly efficient ART scale-up scenarios using local salaries, lowest drug prices, optimized patient loads, and inclusion of viral load (VL) testing. Findings Among 197 individuals enrolled in the EARLI Study, median pre-ART CD4+ cell count was 569/uL (IQR 451–716). Observed ART delivery cost was $628 ppy at steady state. Models using local salaries and only core laboratory tests estimated costs of $529/$445 ppy (+/-VL testing, respectively). Models with lower salaries, lowest ART prices, and optimized healthcare worker schedules reduced costs by $100–200 ppy. Costs in a maximally efficient scale-up model were $320/$236 ppy (+/- VL testing). This included $39 for personnel, $106 for ART, $130/$46 for laboratory tests, and $46 for administrative/other costs. A key limitation of this study is its derivation and extrapolation of costs from one large rural treatment program of high CD4+ count individuals. Conclusions In a Ugandan HIV clinic, ART delivery costs—including VL testing—for individuals with CD4>350 were similar to estimates from high-efficiency programs. In higher efficiency scale-up models, costs were substantially lower. These favorable costs may be achieved because high CD4+ count patients are often asymptomatic, facilitating more efficient streamlined ART delivery. Our work provides a framework for calculating costs of efficient ART scale-up models using accessible data from specific programs and regions." @default.
• W2252279491 created "2016-06-24" @default.
• W2252279491 creator A5010247183 @default.
• W2252279491 creator A5023476654 @default.
• W2252279491 creator A5038528504 @default.
• W2252279491 creator A5049249045 @default.
• W2252279491 creator A5052308665 @default.
• W2252279491 creator A5064309709 @default.
• W2252279491 creator A5069551580 @default.
• W2252279491 creator A5076431226 @default.
• W2252279491 creator A5076566887 @default.
• W2252279491 creator A5080925183 @default.
• W2252279491 creator A5083823135 @default.
• W2252279491 date "2015-12-03" @default.
• W2252279491 modified "2023-09-28" @default.
• W2252279491 title "Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda" @default.
• W2252279491 cites W1579399611 @default.
• W2252279491 cites W1968805308 @default.
• W2252279491 cites W1988571126 @default.
• W2252279491 cites W1996430337 @default.
• W2252279491 cites W2001549763 @default.
• W2252279491 cites W2003501480 @default.
• W2252279491 cites W2006464238 @default.
• W2252279491 cites W2007699466 @default.
• W2252279491 cites W2009115424 @default.
• W2252279491 cites W2017271474 @default.
• W2252279491 cites W2019747537 @default.
• W2252279491 cites W2023406362 @default.
• W2252279491 cites W2029384044 @default.
• W2252279491 cites W2032214005 @default.
• W2252279491 cites W2052409578 @default.
• W2252279491 cites W2056471472 @default.
• W2252279491 cites W2057543772 @default.
• W2252279491 cites W2063578992 @default.
• W2252279491 cites W2077033962 @default.
• W2252279491 cites W2098957040 @default.
• W2252279491 cites W2099307135 @default.
• W2252279491 cites W2116560165 @default.
• W2252279491 cites W2128431602 @default.
• W2252279491 cites W2128478603 @default.
• W2252279491 cites W2134327807 @default.
• W2252279491 cites W2142299478 @default.
• W2252279491 cites W2143265231 @default.
• W2252279491 cites W2145564716 @default.
• W2252279491 cites W2151362414 @default.
• W2252279491 cites W2158326431 @default.
• W2252279491 cites W2164487529 @default.
• W2252279491 cites W2169980588 @default.
• W2252279491 cites W2170719678 @default.
• W2252279491 cites W2313234222 @default.
• W2252279491 cites W2403671454 @default.
• W2252279491 doi "https://doi.org/10.1371/journal.pone.0143433" @default.
• W2252279491 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4669141" @default.
• W2252279491 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26632823" @default.
• W2252279491 hasPublicationYear "2015" @default.
• W2252279491 type Work @default.
• W2252279491 sameAs 2252279491 @default.
• W2252279491 citedByCount "14" @default.
• W2252279491 countsByYear W22522794912017 @default.
• W2252279491 countsByYear W22522794912018 @default.
• W2252279491 countsByYear W22522794912019 @default.
• W2252279491 countsByYear W22522794912020 @default.
• W2252279491 countsByYear W22522794912021 @default.
• W2252279491 crossrefType "journal-article" @default.
• W2252279491 hasAuthorship W2252279491A5010247183 @default.
• W2252279491 hasAuthorship W2252279491A5023476654 @default.
• W2252279491 hasAuthorship W2252279491A5038528504 @default.
• W2252279491 hasAuthorship W2252279491A5049249045 @default.
• W2252279491 hasAuthorship W2252279491A5052308665 @default.
• W2252279491 hasAuthorship W2252279491A5064309709 @default.
• W2252279491 hasAuthorship W2252279491A5069551580 @default.
• W2252279491 hasAuthorship W2252279491A5076431226 @default.
• W2252279491 hasAuthorship W2252279491A5076566887 @default.
• W2252279491 hasAuthorship W2252279491A5080925183 @default.
• W2252279491 hasAuthorship W2252279491A5083823135 @default.
• W2252279491 hasBestOaLocation W22522794911 @default.
• W2252279491 hasConcept C142462285 @default.
• W2252279491 hasConcept C144024400 @default.
• W2252279491 hasConcept C144133560 @default.
• W2252279491 hasConcept C149923435 @default.
• W2252279491 hasConcept C162853370 @default.
• W2252279491 hasConcept C164624739 @default.
• W2252279491 hasConcept C205649164 @default.
• W2252279491 hasConcept C2778755073 @default.
• W2252279491 hasConcept C2993143319 @default.
• W2252279491 hasConcept C3013748606 @default.
• W2252279491 hasConcept C512399662 @default.
• W2252279491 hasConcept C58640448 @default.
• W2252279491 hasConcept C71924100 @default.
• W2252279491 hasConceptScore W2252279491C142462285 @default.
• W2252279491 hasConceptScore W2252279491C144024400 @default.
• W2252279491 hasConceptScore W2252279491C144133560 @default.
• W2252279491 hasConceptScore W2252279491C149923435 @default.
• W2252279491 hasConceptScore W2252279491C162853370 @default.
• W2252279491 hasConceptScore W2252279491C164624739 @default.
• W2252279491 hasConceptScore W2252279491C205649164 @default.
• W2252279491 hasConceptScore W2252279491C2778755073 @default.
• W2252279491 hasConceptScore W2252279491C2993143319 @default.

• next